Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02753790 · ClinicalTrials.gov registry record · NA
Whole Brain Radiation Using IMRT for Patients With Brain Metastases
A NA study, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- NA
- Development phase
- 29
- Enrollment target
NCT02753790 is a NA study that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 29 participants.
The verdict
NCT02753790, a NA study, has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- NA
- Development phase
- 29 participants
- Enrollment target
Study Summary
Some cancers can spread, or metastasize, to the brain. When they do, treatment often involves surgery and/or radiation. Optimal treatment of brain metastases would maximize disease control and minimize toxicity (or side effects), and improve the quality of life of patients. A common type of radiation used for brain metastases is called whole brain radiation, which treats not just the cancer that can be seen on scans (i.e., gross disease), but the smaller sites of cancer that may not be visible (i.e. subclinical disease). Fractionation is used to describe repetitive treatments in which small doses (fractions) of a total planned dose are given at separate clinic visits. The most common dosing regimen is 30 Gray (Gy), using 3 Gy per fraction over 10 fractions. Previous studies have suggested that using intensity modulated radiation therapy (IMRT) may be a safer way to deliver higher doses to gross disease and lower doses to the rest of the brain that may contain subclinical disease. This approach may spare the rest of the brain from radiation complications and side effects. The goal of this study is to determine whether using IMRT to treat brain metastases is more effective than current standard whole brain radiation in controlling gross disease and whether patient quality of life and hair loss is improved compared to previous studies using whole brain radiation.
Interventions
- RADIATION Intensity Modulated Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2016-03-09 |
| Est. Completion | 2022-04-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02753790
The ClinicalTrials.gov registry entry for NCT02753790 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intensity Modulated Radiotherapy is the first listed.
NCT02753790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02753790 about?
NCT02753790 is a clinical study titled "Whole Brain Radiation Using IMRT for Patients With Brain Metastases". Some cancers can spread, or metastasize, to the brain. When they do, treatment often involves surgery and/or radiation. Optimal treatment of brain metastases would maximize disease control and minimize toxicity (or side effects), and improve the quality of life of patients. A common type of radiatio...
What is the current status of trial NCT02753790?
This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2016-03-09. Estimated completion is 2022-04-10.
What interventions are being tested in trial NCT02753790?
The interventions under investigation include: Intensity Modulated Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT02753790?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.